Cancer is still a big problem

Cancer is still a big problem

Cancer is still a major global health problem. In the U.S. alone, more than 600,000 people die from cancer each year, even though over $20 billion per year is spent on research.  The most advanced cancer treatments cost more than $400,000, which is not affordable for the average person. To make things worse, the cost and time of drug development is only increasing, which means these issues will not be solved soon.

We are pioneering
a platform for making artificial viruses
to create precision cancer therapies

Viruses are the most abundant biological entity on earth, and have broad utility in research and medical applications. Some are even known to kill cancer cells, these are called oncolytic viruses.

To make the best possible oncolytic viruses, we will design them (on a computer) and then synthesize and assemble them. Through this process, we can make precision treatments, specifically engineered for each patient with maximum therapeutic effect.

Oncolytic viruses

Computer Aided Design

Personalized for each patient to effectively kill cancer

What we do

We identify the unique aspects of each patient’s tumor using next-generation sequencing. Next, we use our proprietary design software and digital library to engineer an oncolytic virus that is tailor-made for each patient. We then use state-of-the-art DNA synthesis and laboratory robotics to physically build the oncolytic viruses. Finally, we test our therapies on cancer cells collected from patient’s biopsies, so we know they are safe and work.

We envision a world where cancer therapies are available for everyone at an affordable price. To make this a reality, we are on a mission to build an end-to-end platform for developing synthetic viruses and manufacture these therapies at scale. We are pioneering Drug Development as a Service, completed in weeks, not years.

Our initial efforts are focused on cancer therapeutics for dogs. After we validate our platform, we will pursue the development of synthetic oncolytic virus therapies for humans.